mail2

Spectrum Library

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

Sci China Life Sci. 2016 Feb 26. [Epub ahead of print]

Yan Y1, Li Y2, Fu Y2, Yang L2, Su L2, Shi K2, Li M2, Liu Q2,3, Borazanci A3, Liu Y2, He Y4, Bennett JL5, Vollmer TL5, Shi FD6,7.

Abstract

We characterized a unique group of patients with neuromyelitis optica spectrum disorder (NMOSD) who carried autoantibodies of aquaporin-4 (AQP4) and myelin-oligodendrocyte glycoprotein (MOG). Among the 125 NMOSD patients, 10 (8.0%) were AQP4- and MOG-ab double positive, and 14 (11.2%) were MOG-ab single positive. The double-positive patients had a multiphase disease course with a high annual relapse rate (P=0.0431), and severe residual disability (P>0.0001). Of the double- positive patients, 70% had MS-like brain lesions, more severe edematous, multifocal regions on spinal magnetic resonance imaging (MRI), pronounced decreases of retinal nerve fiber layer thickness and atrophy of optic nerves. In contrast, patients with only MOG-ab had a higher ratio of monophasic disease course and mild residual disability. Spinal cord MRI illustrated multifocal cord lesions with mild edema, and brain MRIs showed more lesions around lateral ventricles. NMOSD patients carrying both autoantibodies to AQP4 and MOG existed and exhibited combined features of prototypic NMO and relapsing- remitting form of MS, whereas NMOSD with antibodies to MOG only exhibited an “intermediate” phenotype between NMOSD and MS. Our study suggests that antibodies against MOG might be pathogenic in NMOSD patients and that determination of anti-MOG antibodies maybe instructive for management of NMOSD patients.

KEYWORDS:

AQP4 antibody; MOG antibody; neuromyelitis optica spectrum disorder; phenotype

PMID:
26920678
DOI:
10.1007/s11427-015-4997-y